| |
| ・ |
H.I.Ali,K.Tomita,E.Akaho,M.Kunishima,Y.Kawashima,T.yamagishi,H.Ikeya,T.Nagamatsu,“Antitumor
studies-Part2:Structure-activity relationship study
for flavin analogs including investigations on their
in vitro antitumor assay and docking simulation into
protein tyrosine kinase,”Eur.j.Med.Chem.43,1376-1389(2008) |
| ・ |
K.Takamatsu,A.Takano,N.Yakushiji,K.Morishita,N.Matsuura,M.Makishima,H.I.Alie,E.Akaho,A.Tai,K.Sasaki,H.Kakuta,“Reduction
of lipophilicty at the lipophilic domain of RXR agonists enables
production of subtype-Preference:RXRa-preferential
agonist possessing a sulfonamide
moiety,”Chem.Med.Chem.,DOI:10.1002/cmdc.(2007) |
| ・ |
H.A.Ali,K.Tomita,E.Akaho,H.Kambara,S.Miura,S.Hayakawa,N.Ashida,Y.Kawashima,T.Yamagishi,H.Ikeya,F.Yoneda,T.Nagamatsu,“Antitumor
studies.Part1:design,synthesis,antitumor activity,and
AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and
2-deoxo-2-phenylflavin-5-oxides as a new class of
antitumor agents,”Bioorg.Med.Chem., 15 242-256(2007) |
| ・ |
X.Zheng,H.Oda,K.Takamatsu,Y.Sugimoto,A.Tai,E.Akaho,H.I.Ali,T.Oshiki,H.Kakuta.,S.Sasaki,“Analgesic
agents without gastric damage:design and synthesis of
structurally simple benzensulfonamide-type
cyclooxygenase-1-selective inhibitors,”Bioorg.Med.Chem.,15
1014-1021(2007) |
| ・ |
H. Kambara, T. Yamada, M. Tsujioka, S. Matsunaga,
R. Tanaka, I.H. Ali, C. Wiart, M. Yusof, H. Hassan, A.
Hanifah, A.M. Fauzi, N.H. Mazlan, M. Jay, M. Kunishima,
E. Akaho, “A study on medicinal plants from Malaysia
focused on Acalypha siamensis OLIV. Ex.
GAGE.-isolation and structure of a new
tetraterpene,Acalyphaser A,”Chem. & Biodivers.,3
1301-6(2006) |
| ・ |
E. Akaho, M. Hirai, M.D. Katz, C. Umezawa,“Ｅｖｉｄｅｎｃｅ−based
ｐｒａｃｔｉｃｅ characterized ｂｙ ｎｕｍｂｅｒ needed ｔｏ ｔｒｅａｔ ａｓ
pharmacist's ｂａｓｉｃ ｒｅｓｐｏｎｓｉｂｉｌｉｔｙ,” Japan. J. Drug
Inf., 7(4) 272-82 (2006) |
|
|
|
